01652 FUSEN PHARM
- 0.900
- +0.030+3.45%
FUSEN PHARM News
Insider Buying: Fusen Pharmaceutical Executive Chairman Bought CN¥908k Of Shares
Investors who take an interest in Fusen Pharmaceutical Company Limited (HKG:1652) should definitely note that the Executive Chairman, Changcheng Cao, recently paid HK$0.87 per share to buy HK$908k wor
福森藥業：年報2023
Forson Pharmaceutical (01652.HK): Application for marketing license for “Compound Potassium Hydrogen Phosphate Injection” was accepted
Gelonghui, April 23 | Forson Pharmaceutical (01652.HK) announced that the compound potassium hydrogen phosphate injection developed by Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd., a wholly-owned subsidiary of the Group, has submitted a marketing application to the China National Drug Administration and has been accepted for the treatment of the following diseases: as a phosphorus supplement in complete parenteral nutritional therapy; it can also be used for hypophosphatemia caused by certain diseases. Phosphorus is involved in sugar phosphorylation in sugar metabolism, making up phospholipids in membrane components, and is an important component of RNA, DNA, and many coenzymes in cells. Phosphorus is also involved in energy storage, conversion, and body fluid buffering functions
Forson Pharmaceutical (01652) spent about HK$546,900 to buy back 648,000 shares on April 17
Forson Pharmaceutical (01652) announced that on April 17, 2024, it cost about HK$546,900 to buy back 64.8...
Forson Pharmaceuticals (01652.HK) spent HK$581,500 to buy back 676,000 shares on April 16
On April 16, Gelonghui | Forson Pharmaceutical (01652.HK) announced that it spent HK$581,500 to buy back 676,000 shares on April 16.
Fussen Pharmaceutical (01652.HK) plans to establish a limited partnership to explore diversified business development
Gelonghui, April 16, 丨 Fussen Pharmaceutical (01652.HK) announced that on April 16, 2024, Henan Fusen, an indirect wholly-owned subsidiary of the company (as limited partner A), entered into a limited partnership agreement with the general partner and limited partner B to establish a limited partnership. Henan Fusen's total capital commitment is RMB 85 million, which will be disbursed using the Group's internal resources. The limited partnership will engage in investment business and participate in investing in different potential pharmaceutical-related enterprises or projects. Qingdao Qiji Electronic Technology Co., Ltd. is a limited company established in China. Limited partner B is mainly engaged in corporate investment and equity
Fussen Pharmaceutical (01652):. The marketing application for “metformin englicin tablets (I)” was submitted and accepted
Zhitong Finance App News, Fussen Pharmaceutical (01652) announced that the “metformin englicin tablets (I)” developed by Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd., a wholly-owned subsidiary of the Group, has submitted a marketing application to the China National Drug Administration and has been accepted for the treatment of the following diseases: This product is used in combination with diet control and exercise, and is suitable for adult patients with type 2 diabetes who are being treated with engagliflozin and metformin hydrochloride to improve blood sugar control in these patients. “Metformin Engagliptin Tablets (I)” is a compound preparation composed of metformin hydrochloride and engagliflozin. The pharmacological effects are as follows: 2
Fusen Pharmaceutical Posts Higher Loss in 2023
Fusen Pharmaceutical (HKG:1652) reported a loss attributable to the equity shareholders of 36.3 million yuan for the year ended Dec. 31, 2023, compared with a loss of 34.6 million yuan in the previous
Fusen Pharmaceutical Company Limited (HKG:1652) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely
Unfortunately for some shareholders, the Fusen Pharmaceutical Company Limited (HKG:1652) share price has dived 26% in the last thirty days, prolonging recent pain. The drop over the last 30 days ha
Fuson Pharmaceutical (01652) announced the 2023 annual results, shareholders should account for 36.277 million yuan, an increase of 4.83% year-on-year
Fussen Pharmaceutical (01652) announced results for the year ended December 31, 2023, and the group made profits during the period...
FUSEN PHARM: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
Fussen Pharmaceutical (01652.HK) plans to hold a board meeting on March 28 to consider and approve the annual results
Glonghui, March 18, 丨 Fussen Pharmaceutical (01652.HK) announced that the board of directors will meet on March 28, 2024 (Thursday) to consider and approve the annual results and announcements of the company and its subsidiaries for the year ended 31 December 2023, and to consider the payment of a final dividend (if any).
FUSEN PHARM: NOTICE OF BOARD MEETING
Fuson Pharmaceuticals (01652) estimates annual shareholders' losses of about 35 million to 43 million yuan
Fussen Pharmaceutical (01652) announced that it is expected that the Group's companies for the year ended December 31, 2023 will...
FUSEN PHARM: PROFIT WARNING
CICC: The pharmaceutical sector has entered the value investment range. It is recommended to focus on overseas exports and opportunities to increase the localization rate
CICC released a research report saying that after more than 2 years of systematic adjustments, the pharmaceutical sector has entered the value investment range.
Forson Pharmaceuticals (01652.HK) spent HK$2.85 million to buy back 2.16 million shares on January 25
On January 25, Gelonghui | Forson Pharmaceutical (01652.HK) announced that on January 25, it spent HK$2.85 million to repurchase 2.16 million shares at a price of HK$1.29-1.33 per share.
Zheshang Securities: What are the marginal changes and investment logic of the pharmaceutical sectors in 2023Q4?
The Zhitong Finance App learned that against the backdrop of high base figures for some products in the 2022 Q4 and 2023Q1 pharmaceutical sector, the bank is more optimistic about digesting undervaluation and investment opportunities with the logic of going overseas.
Pioneer Securities Pharmaceutical's 24-year Strategy: Risks have been fully released, and subsequent industry valuations are expected to rise steadily
The Zhitong Finance App learned that Pioneer Securities released a research report saying that due to more scientific collection rules, after the collection gradually covered a large stock of generic drugs/high-value consumables, the performance was clear, and new performance growth points were formed after innovative products were launched one after another, and the drugs/device-related companies in the hospital will usher in a new growth cycle after their performance stabilizes.
CITIC Securities: Healthcare Faces Deepening Changes and Focusing on Seven Major Prospects of Industrial Trends
CITIC Securities released a research report saying that in 2023 in the post-pandemic era, the healthcare industry ushered in the harshest anti-corruption storm in nearly 20 years. Combined with frequent biomedical industry policies in recent years, industrial development has ushered in profound changes, and sector valuations and public fund allocations are also at historically relatively low levels.
Analysis
Price Target
No Data
